Clinical Trial Update: RTX001 Autologous Engineered Macrophages for Liver Cirrhosis [Phase 1, Phase 2]

View source ↗

Summary

RTX001 is an autologous engineered macrophage therapy being investigated in Phase 1/2 trials for end-stage liver disease and liver cirrhosis, with recruitment o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Decompensated Cirrhosis
• End-stage Liver Disease
• Liver Cirrhosis
• Liver Disease
• Liver Fibrosis
• Nonalcoholic Fatty Liver Disease

Drugs mentioned

• RTX001

Snippet

Sponsor: Resolution Therapeutics Limited | Conditions: End-stage Liver Disease (ESLD), Cirrhosis, Liver | Phase 1, Phase 2 | Status: RECRUITING